Feb 27 2026

george

March. 2026 Cheat Sheet

Click March 2026 Cheat Sheet for your Fritsma Factor monthly Cheat Sheet that summarizes our February posts and those before. If you’d like a push copy of the Cheat Sheet, updated with links to last month’s posts, complete the brief form at the right. The Cheat Sheet, Quick Questions, posts, informative PowerPoint modules, and more […]

read more

Comments (0)

Cheat Sheets

Feb 27 2026

george

March 2026 QQ: LAC Testing When the Patient is on DOAC

Our March 2026 Quick Question is a poll that asks, “How do you test for LAC when the patient is on a DOAC?” This question arises from the discussion in our 2-19-26 post, “CAP Today: Hemostasis Testing While on DOACs.” Often, the provider requests LAC testing for a thrombosis patient on anticoagulation. While the anticoagulant […]

read more

Comments (0)

Anticoagulant Therapy

Feb 27 2026

george

February 2026 QQ Results: DOAC Names

Our February 2026 Quick Question was a quiz that drew 42 responses. The stem asked, “Which DOAC is a direct thrombin inhibitor?” Your answers: Apixaban: 9 (21%) Betrixaban: 0 Dabigatran: 32 (76%) Edoxaban: 0 Rivaroxaban: 1 (3%) We performed well on this question. No one chose betrixaban, an FXa-directed oral anticoagulant that was withdrawn in […]

read more

Comments (1)

Anticoagulant Therapy

Feb 25 2026

george

Case Series: Emicizumab Therapy in Acquired Hemophilia A

Here is an open-access article describing emicizumab Rx in acquired hemophilia A: Calcaterra I, De Luca C, D’Errico G, et al. Emicizumab in acquired hemophilia A: a real-world case series with patient-level outcome analysis. Semin Thromb Hemost. 2026 doi: 10.1055/a-2788-1642. Epub ahead of print. PMID: 41534873. Abstract Acquired Hemophilia A (AHA) is a rare bleeding […]

read more

Comments (0)

Bleeding Disorders

Feb 25 2026

george

Diagnostic Equity Question: INR is 3.9

This question appeared 2-24-26 on the Diagnostic Equity website: “I’m on warfarin for atrial fibrillation, and my INR today is 3.9. The target range is 2.0–3.0. I haven’t changed my diet or missed any doses. What factors could cause my INR to drift this high unexpectedly, and when does an elevated INR become an emergency?” […]

read more

Comments (0)

Anticoagulant Therapy

Feb 24 2026

george

Field Study Compares OSA With CSA for Measuring Efanesoctocog Alfa

Here is an open-access article contrasting the validity of OSA versus CSA for measuring efanesoctocog alfa (Altuviiio®) spiked into normal plasma: Pipe S, Sadeghi-Khomami A, Konkle BA, et al. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia. […]

read more

Comments (0)

Factor Assays

Feb 22 2026

george

JTH Editorial: The Problem With Coagulopathy…

Click here for the open-access editorial Thachil J. The problem with coagulopathy …. J Thromb Haemost. 2022;20:2171-2172. doi: 10.1111/jth.15795. PMID: 35733290. Abstract Coagulopathy is inextricably linked to the field of hemostasis and thrombosis. In the same manner, hemostasis and thrombosis may deal with bleeding and clot formation; coagulopathy also may be connected to bleeding or […]

read more

Comments (0)

Global Hemostasis Assays

Feb 21 2026

george

Review: Non-antithrombotic Strategies for Venous Thromboembolism Prophylaxis

Check with your medical library for this provocative review of VTE prevention: Gurumurthy G, Thachil J. Nonanticoagulant strategies for venous thromboembolism prophylaxis. Semin Thromb Hemost. 2026;52:236–47. doi: 10.1055/a-2712-3534. PMID: 41092960. Abstract Venous thromboembolism (VTE) remains a major cause of preventable morbidity and mortality. Prophylaxis with anticoagulation is limited by bleeding risk, contraindications, and patient-specific factors. […]

read more

Comments (0)

Thrombophilia

Feb 19 2026

george

CAP Today: Hemostasis Testing While on DOACs

This open-access January 26 CAP Today document features the opinions of several experts as they address the limitations of coagulation testing in patients taking DOACs, such as dabigatran, rivaroxaban, or apixaban, and speculates on the coagulation effects of the upcoming anti-XI antithrombotics: Direct Oral Anticoagulants–New Guidance, Lab Testing.

read more

Comments (0)

Anticoagulant Therapy

Feb 17 2026

george

Case: Essential Thrombocythemia

Here is a February 16, 2026, question addressed to the Diagnostic Equity website: “I have essential thrombocythemia (ET). Can I live a normal life, and will my labs be a barometer for how I am doing?” Here is the response excerpted by colleague Kathryn Golab, DCLS: ET is a disorder of the early blood-forming cells […]

read more

Comments (0)

Arterial Thrombosis